Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial

Key Points

• Varnimcabtagene shows promise in treating relapsed or refractory acute lymphoblastic leukaemia in adults, achieving positive outcomes.
• In a phase 2 trial, 75% of participants responded favorably by the end of treatment, indicating substantial potential.
• This multicentre trial demonstrated effective immunotherapy approaches for acute lymphoblastic leukaemia management.
• Findings suggest that varnimcabtagene autoleucel could become a new standard in treating relapsed cases of this leukaemia.